Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to $19.2 million.

  • Rapid Micro Biosystems' Cash from Financing Activities rose 3145245.9% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 970812.18%. This contributed to the annual value of $203000.0 for FY2024, which is 3624.16% up from last year.
  • According to the latest figures from Q3 2025, Rapid Micro Biosystems' Cash from Financing Activities is $19.2 million, which was up 3145245.9% from -$298000.0 recorded in Q2 2025.
  • Over the past 5 years, Rapid Micro Biosystems' Cash from Financing Activities peaked at $139.3 million during Q3 2021, and registered a low of -$1.4 million during Q2 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $61000.0 (2024), whereas its average is $12.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 278608000.0% in 2021, then crashed by 288000.0% in 2025.
  • Rapid Micro Biosystems' Cash from Financing Activities (Quarter) stood at -$1.3 million in 2021, then surged by 106.93% to $87000.0 in 2022, then tumbled by 113.79% to -$12000.0 in 2023, then skyrocketed by 50.0% to -$6000.0 in 2024, then soared by 320883.33% to $19.2 million in 2025.
  • Its Cash from Financing Activities stands at $19.2 million for Q3 2025, versus -$298000.0 for Q2 2025 and $379000.0 for Q1 2025.